Antifungal therapy forms the mainstay of treatment of the infections caused by Candida. These agents include azoles (fluconazole, triazole, ketoconazole), nystatin, and amphoteri-cin B. C. glabrata is becoming increasingly important worldwide and is intrinsically less susceptible to amphotericin B and other azoles (ketoconazole, fluconazole, etc). Candida krusei is increasingly recognized because of its resistance to many anti-fungal agents. It is intrinsically resistant to ketoconazole and fluconazole. It is also less susceptible to all other antifungal agents including itraconazole and amphotericin B. C. lusitaniae is also of clinical significance because it is resistant to ampho-tericin B, but it is susceptible to azoles and echinocandins.
Antifungal prophylaxis is indicated for patients with invasive candidiasis who are at high risk of developing invasive candi-diasis. There is no vaccine available against candidiasis.